Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19005540 | PREPARATION AND APPLICATION OF HIGH-ACTIVITY AND HIGH-SAFETY CARDAMINE VIOLIFOLIA SELENOPROTEIN STANDARD SAMPLE | December 2024 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 18885661 | POLYMERASE MUTANT AND APPLICATIONS THEREOF | September 2024 | February 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18656340 | HUMAN ALPHA-GALACTOSIDASE VARIANTS | May 2024 | November 2024 | Allow | 6 | 0 | 0 | Yes | No |
| 18654723 | PROCESS FOR PRODUCTION OF A SOLUBLE AND INSOLUBLE COLLAGEN PRODUCT FROM MAMMALIAN DERMIS TISSUE | May 2024 | August 2024 | Allow | 4 | 1 | 1 | Yes | No |
| 18634776 | OLIGOSACCHARIDE DEBRANCHING ENZYME MUTANT AND USE THEREOF IN GLUCOSE MOTHER LIQUOR | April 2024 | April 2025 | Allow | 12 | 0 | 0 | Yes | No |
| 18587665 | Methods of Adding Polymers to Ribonucleic Acids | February 2024 | February 2025 | Allow | 12 | 0 | 1 | Yes | No |
| 18682024 | METHOD FOR PRODUCING A RECOMBINANT BACTERIAL COLLAGEN-LIKE PROTEIN (CLP) | February 2024 | September 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18424277 | ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOME | January 2024 | June 2025 | Abandon | 17 | 1 | 1 | No | No |
| 18391409 | PDE5A DESTABILIZING DOMAINS | December 2023 | April 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18544275 | FUSION CONSTRUCTS AS PROTEIN OVER-EXPRESSION VECTORS | December 2023 | April 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18540631 | PROCESS FOR PRODUCTION OF SUGAR FROM A COTTON-CONTAINING TEXTILE | December 2023 | March 2025 | Abandon | 15 | 1 | 1 | No | No |
| 18530082 | ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATES | December 2023 | April 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18526930 | COUPLING ENDONUCLEASES WITH END-PROCESSING ENZYMES DRIVES HIGH EFFICIENCY GENE DISRUPTION | December 2023 | April 2025 | Allow | 16 | 1 | 1 | Yes | No |
| 18519620 | POLYMERASE ENZYME FROM 9�N | November 2023 | March 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18493395 | ATTENUATED GLUTAMINE SYNTHETASE AS A SELECTION MARKER | October 2023 | January 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18286782 | PROCESS TO PRODUCE MONO-RHAMNOLIPIDS | October 2023 | March 2025 | Allow | 17 | 4 | 0 | Yes | No |
| 18461604 | OLIGOPEPTIDE WITH LIPID-LOWERING ACTIVITY, PREPARATION METHOD AND APPLICATION THEREOF | September 2023 | June 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18462237 | ENGINEERED AMYLASE VARIANTS | September 2023 | April 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18455342 | METHODS FOR OPTIMIZING GAS UTILIZATION | August 2023 | May 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18448856 | RNA POLYMERASE VARIANTS | August 2023 | August 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18446758 | CARBON SEQUESTRATION IN SOILS WITH PRODUCTION OF CHEMICAL PRODUCTS | August 2023 | September 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18226833 | Method for Modifying Polyester by Swelling Agent Combined with Cutinase | July 2023 | January 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18354044 | METHODS FOR CO-PRODUCING ERYTHRITOL AND ARABINOSE BY USING XYLOSE MOTHER LIQUOR | July 2023 | October 2023 | Allow | 2 | 0 | 0 | No | No |
| 18267874 | ALLULOSE EPIMERASE VARIANT WITH EXCELLENT THERMAL STABILITY, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR ALLULOSE USING SAME | June 2023 | October 2024 | Allow | 16 | 0 | 0 | No | No |
| 18323090 | CELL | May 2023 | September 2024 | Allow | 16 | 1 | 0 | No | No |
| 18316222 | Genus Hydrogenophilus Bacterium Transformant | May 2023 | August 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18316224 | Genus Hydrogenophilus Bacterium Transformant | May 2023 | August 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18310744 | TETHERED INTERLEUKIN-15 AND INTERLEUKIN-21 | May 2023 | September 2024 | Allow | 17 | 3 | 1 | Yes | No |
| 18308336 | CRISPR/CAS FUSION PROTEINS AND SYSTEMS | April 2023 | February 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18132279 | Activated Formylglycine-Generating Enzymes and Methods of Producing and Using the Same | April 2023 | February 2024 | Allow | 10 | 0 | 0 | No | No |
| 18130560 | COMPOSITIONS AND METHODS RELATING TO NUCLEIC ACID INTERACTION REPORTERS | April 2023 | July 2024 | Allow | 15 | 2 | 1 | Yes | No |
| 18182481 | METHOD FOR PREPARING XYLOGLUCAN-OLIGOSACCHARIDES | March 2023 | September 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18112968 | METHODS AND STRAIN | February 2023 | November 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 18163496 | Fc GLYCAN REMODELING PLATFORM METHOD FOR SITE-SPECIFIC ANTIBODY CONJUGATION AND APPLICATIONS THEREOF | February 2023 | May 2024 | Allow | 16 | 2 | 1 | Yes | No |
| 18018303 | PROCESSES FOR REDUCING STEAM CONSUMPTION AND IMPROVING PROCESS CARBON BALANCE IN BIOMASS CONVERSION TO SUGARS, BIOCHEMICALS, BIOFUELS, AND/OR BIOMATERIALS | January 2023 | March 2024 | Allow | 13 | 1 | 1 | Yes | No |
| 18158339 | PENICILLIN-G ACYLASES | January 2023 | April 2024 | Allow | 15 | 0 | 1 | Yes | No |
| 18155541 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM, ARDS, AND ACUTE LUNG INJURY USING BETA-GLUCOCEREBROSIDASE | January 2023 | August 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18150018 | LUCIFERASE-BASED THERMAL SHIFT ASSAYS | January 2023 | September 2023 | Allow | 9 | 0 | 0 | Yes | No |
| 18148284 | PROTEIN COMPLEX BASED ON DNA ENZYMES OF E FAMILY OF ESCHERICHIA COLI AND APPLICATION THEREOF IN ARTIFICIAL PROTEIN SCAFFOLDS | December 2022 | December 2023 | Allow | 11 | 2 | 1 | Yes | No |
| 18080631 | MICROBIAL STEM CELL TECHNOLOGY | December 2022 | June 2025 | Allow | 30 | 2 | 0 | Yes | No |
| 18000246 | METHOD FOR IMPROVING PRODUCTIVITY OF 2'-FUCOSYLLACTOSE THROUGH ENZYMATIC TREATMENT | November 2022 | May 2023 | Allow | 5 | 0 | 0 | Yes | No |
| 18050224 | XANTHAN LYASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | October 2022 | August 2024 | Abandon | 21 | 1 | 1 | No | No |
| 17960099 | SIMULTANEOUS ENZYMATIC CELLULOSE HYDROLYSIS AND PRODUCT SEPARATION IN A RADIAL-FLOW MEMBRANE BIOREACTOR | October 2022 | June 2023 | Allow | 8 | 1 | 0 | No | No |
| 17936076 | PROCESSES FOR PRODUCING A FERMENTATION PRODUCT | September 2022 | December 2024 | Allow | 26 | 3 | 0 | Yes | No |
| 17942774 | RECOMBINANT HOST CELL WITH ALTERED MEMBRANE LIPID COMPOSITION | September 2022 | May 2024 | Allow | 20 | 2 | 0 | Yes | No |
| 17822789 | SELF-STERILIZING FABRICS INCORPORATING ANTI-VIRAL COLD-ACTIVE PROTEASES | August 2022 | May 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17905064 | MODIFIED POLYPEPTIDE HAVING MANNANASE ACTIVITY | August 2022 | January 2025 | Allow | 29 | 0 | 0 | No | No |
| 17904213 | GLYCOMINIMIZED BACTERIAL HOST CELLS | August 2022 | July 2024 | Abandon | 23 | 2 | 2 | Yes | No |
| 17817413 | COMPOSITIONS AND METHODS FOR ENHANCED PRODUCTION OF ENDURACIDIN IN A GENETICALLY ENGINEERED STRAIN OF STREPTOMYCES FUNGICIDICUS | August 2022 | August 2023 | Allow | 12 | 0 | 0 | Yes | No |
| 17759261 | HMO PRODUCTION | July 2022 | March 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 17813088 | EXPRESSION VECTOR | July 2022 | April 2025 | Allow | 33 | 5 | 0 | Yes | No |
| 17812460 | ACID-ALPHA GLUCOSIDASE VARIANTS AND USES THEREOF | July 2022 | January 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17811051 | CELL-FREE GLYCOPROTEIN SYNTHESIS (CFGPS) IN PROKARYOTIC CELL LYSATES ENRICHED WITH COMPONENTS FOR GLYCOSYLATION | July 2022 | June 2024 | Allow | 23 | 3 | 0 | Yes | No |
| 17857624 | MUTANT THIOESTERASES | July 2022 | April 2024 | Allow | 21 | 0 | 1 | Yes | No |
| 17852907 | E. COLI STRAINS HAVING AN OXIDATIVE CYTOPLASM | June 2022 | January 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 17788620 | ALLULOSE EPIMERASE VARIANT, METHOD FOR PREPARING THE SAME, AND METHOD FOR PREPARING ALLULOSE USING THE SAME | June 2022 | January 2023 | Allow | 6 | 0 | 0 | Yes | No |
| 17787558 | METHOD FOR PREPARING RECOMBINANT HUMAN NERVE GROWTH FACTOR | June 2022 | May 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17786885 | BINDING PROTEINS FOR THE ENZYME ACID ALPHA GLUCOSIDASE (GAA) AND USES THEREOF | June 2022 | January 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17839233 | FUSION PROTEINS AND METHODS FOR SITE-DIRECTED GENOME EDITING | June 2022 | January 2024 | Allow | 19 | 1 | 0 | No | No |
| 17837660 | EFFICIENT PRODUCT CLEAVAGE IN TEMPLATE-FREE ENZYMATIC SYNTHESIS OF POLYNUCLEOTIDES | June 2022 | October 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17828131 | COMPOSITIONS AND METHODS FOR TREATING FARBER DISEASE | May 2022 | November 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17824643 | GENETICALLY ENCODED FLUORESCENT SENSORS FOR DETECTING LIGAND BIAS AND INTRACELLULAR SIGNALING THROUGH cAMP PATHWAYS | May 2022 | June 2024 | Allow | 25 | 3 | 0 | No | No |
| 17749796 | PROCESS FOR PRODUCTION OF SUGAR FROM A COTTON-CONTAINING TEXTILE | May 2022 | November 2023 | Allow | 18 | 2 | 1 | Yes | No |
| 17743716 | Genetically Engineered Strain for Producing Porcine Myoglobin and Food-grade Fermentation and Purification Thereof | May 2022 | March 2023 | Allow | 10 | 1 | 1 | Yes | No |
| 17727990 | ACID-ALPHA GLUCOSIDASE VARIANTS AND USES THEREOF | April 2022 | January 2025 | Allow | 33 | 3 | 0 | Yes | No |
| 17724712 | PRODUCTION OF BACTERIOCINS | April 2022 | January 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17724390 | ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATES | April 2022 | September 2023 | Allow | 16 | 0 | 1 | No | No |
| 17699927 | AUGMENTED ACID ALPHA-GLUCOSIDASE FOR THE TREATMENT OF POMPE DISEASE | March 2022 | January 2025 | Allow | 34 | 3 | 0 | Yes | No |
| 17653441 | DPO4 POLYMERASE VARIANTS | March 2022 | February 2024 | Allow | 24 | 1 | 1 | Yes | No |
| 17677670 | INSULIN DERIVATIVES WITH A TERMINAL LPXT MOTIF | February 2022 | October 2023 | Abandon | 20 | 0 | 1 | No | No |
| 17676099 | MEMBRANE BIOREACTOR FOR SIMULTANEOUS ENZYMATIC CELLULOSE HYDROLYSIS AND PRODUCT SEPARATION | February 2022 | September 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17636720 | Blumea Balsamifera Monoterpene Synthase BBTPS3 And Related Biological Materials Thereof and Use Thereof | February 2022 | May 2025 | Allow | 39 | 1 | 0 | Yes | No |
| 17670738 | T5 EXONUCLEASE-BASED METHOD TO IDENTIFY DNA TOPOISOMERASE INHIBITORS | February 2022 | June 2023 | Allow | 16 | 1 | 0 | No | No |
| 17665265 | ENGINEERED MEGANUCLEASES SPECIFIC FOR RECOGNITION SEQUENCES IN THE HEPATITIS B VIRUS GENOME | February 2022 | February 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17550495 | POLYPEPTIDE HAVING LUCIFERASE ACTIVITY | December 2021 | August 2023 | Allow | 20 | 1 | 1 | Yes | No |
| 17548677 | ENGINEERED GLUCOSYLTRANSFERASES | December 2021 | November 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17547836 | CELLULOLYTIC ENZYME COMPOSITIONS AND USES THEREOF | December 2021 | September 2024 | Allow | 33 | 3 | 1 | Yes | No |
| 17454060 | MOLECULAR SWITCHES | November 2021 | May 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17453476 | SYSTEM AND METHOD FOR GENERATING BUBBLES IN A VESSEL | November 2021 | July 2024 | Allow | 33 | 3 | 1 | Yes | No |
| 17474708 | PRODUCTION OF CANNABINOIDS IN YEAST | September 2021 | November 2023 | Allow | 26 | 0 | 1 | Yes | No |
| 17474226 | ALPHA-AMYLASE VARIANTS HAVING IMPROVED PERFORMANCE AND STABILITY | September 2021 | October 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17469386 | CRISPR-CAS SYSTEM FOR CLOSTRIDIUM GENOME ENGINEERING AND RECOMBINANT STRAINS PRODUCED THEREOF | September 2021 | April 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17467318 | SELF-STERILIZING FABRICS INCORPORATING ANTI-VIRAL COLD-ACTIVE PROTEASES | September 2021 | July 2022 | Allow | 11 | 1 | 1 | Yes | No |
| 17460147 | ENGINEERED AMYLASE VARIANTS | August 2021 | May 2023 | Allow | 20 | 1 | 1 | No | No |
| 17408328 | N- AND C-TERMINAL TANDEM TAG SYSTEM FOR PURIFICATION | August 2021 | September 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17445047 | POLYMERASE COMPOSITIONS, METHODS OF MAKING AND USING SAME | August 2021 | July 2023 | Allow | 23 | 1 | 0 | Yes | No |
| 17395282 | ENDOGENOUS LIPASE FOR METAL REDUCTION IN DISTILLERS CORN OIL | August 2021 | January 2024 | Allow | 29 | 2 | 1 | Yes | No |
| 17374262 | LIGASE FUSION PROTEINS AND APPLICATION THEREOF | July 2021 | July 2022 | Allow | 12 | 2 | 1 | Yes | No |
| 17350078 | POLYMERASE ENZYME FROM 9�N | June 2021 | August 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17350662 | RNA POLYMERASE VARIANTS | June 2021 | June 2023 | Allow | 24 | 0 | 1 | Yes | No |
| 17342928 | CHROMATOGRAPHIC METHOD FOR COLLECTING BLOOD COAGULATION FACTOR VII WITH HIGH YIELD | June 2021 | January 2024 | Allow | 31 | 2 | 0 | Yes | No |
| 17336975 | Activated Formylglycine-Generating Enzymes and Methods of Producing and Using the Same | June 2021 | January 2023 | Allow | 19 | 0 | 0 | Yes | No |
| 17327313 | ULTRAMARINE FLUORESCENT PROTEIN, CONSTRUCTION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF PROTEIN SUNSCREEN AGENT | May 2021 | June 2023 | Allow | 25 | 1 | 1 | Yes | No |
| 17323737 | PRODUCTION OF HUMAN MILK OLIGOSACCHARIDES IN MICROBIAL HOSTS WITH ENGINEERED IMPORT / EXPORT | May 2021 | March 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17320866 | METHOD OF MAKING RECOMBINANT SILK AND SILK-AMYLOID HYBRID PROTEINS USING BACTERIA | May 2021 | March 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17321049 | MODIFIED ACTIVIN A | May 2021 | February 2025 | Allow | 45 | 1 | 0 | No | No |
| 17313675 | MICROORGANISMS AND METHODS FOR PRODUCING 2-PYRONE-4,6-DICARBOXYLIC ACID AND OTHER COMPOUNDS | May 2021 | January 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17307609 | SYSTEMS INCLUDING SIMULATED MOVING BED SEPARATORS FOR HIGH PURITY FRUCTOSE PRODUCTION AND RELATED METHODS | May 2021 | April 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17244190 | COUPLING ENDONUCLEASES WITH END-PROCESSING ENZYMES DRIVES HIGH EFFICIENCY GENE DISRUPTION | April 2021 | October 2023 | Allow | 30 | 2 | 1 | Yes | Yes |
| 17244180 | COUPLING ENDONUCLEASES WITH END-PROCESSING ENZYMES DRIVES HIGH EFFICIENCY GENE DISRUPTION | April 2021 | November 2023 | Allow | 31 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MONSHIPOURI, MARYAM.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner MONSHIPOURI, MARYAM works in Art Unit 1651 and has examined 507 patent applications in our dataset. With an allowance rate of 91.1%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 21 months.
Examiner MONSHIPOURI, MARYAM's allowance rate of 91.1% places them in the 74% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by MONSHIPOURI, MARYAM receive 1.06 office actions before reaching final disposition. This places the examiner in the 14% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by MONSHIPOURI, MARYAM is 21 months. This places the examiner in the 83% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +19.9% benefit to allowance rate for applications examined by MONSHIPOURI, MARYAM. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 33.2% of applications are subsequently allowed. This success rate is in the 65% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 51.6% of cases where such amendments are filed. This entry rate is in the 72% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 88.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 61.9% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 21.1% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.